Cynata Financial Statements From 2010 to 2024
| CYYNF Stock | USD 0.19 0.00 0.00% |
Check Cynata Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cynata Therapeutics' main balance sheet or income statement drivers, such as , as well as many indicators such as . Cynata financial statements analysis is a perfect complement when working with Cynata Therapeutics Valuation or Volatility modules.
Cynata |
Cynata Therapeutics Limited Company Operating Margin Analysis
Cynata Therapeutics' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Cynata Therapeutics Operating Margin | (0.78) % |
Most of Cynata Therapeutics' fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cynata Therapeutics Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Based on the recorded statements, Cynata Therapeutics Limited has an Operating Margin of -0.7809%. This is 97.77% lower than that of the Healthcare sector and 99.3% lower than that of the Biotechnology industry. The operating margin for all United States stocks is 85.83% lower than that of the firm.
Cynata Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Cynata Therapeutics's current stock value. Our valuation model uses many indicators to compare Cynata Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cynata Therapeutics competition to find correlations between indicators driving Cynata Therapeutics's intrinsic value. More Info.Cynata Therapeutics Limited is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Cynata Therapeutics' earnings, one of the primary drivers of an investment's value.About Cynata Therapeutics Financial Statements
Cynata Therapeutics stakeholders use historical fundamental indicators, such as Cynata Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Cynata Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Cynata Therapeutics' assets and liabilities are reflected in the revenues and expenses on Cynata Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Cynata Therapeutics Limited. Please read more on our technical analysis and fundamental analysis pages.
Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. Cynata Therapeutics Limited was founded in 2011 and is based in Cremorne, Australia. Cynata Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange.
Currently Active Assets on Macroaxis
Other Information on Investing in Cynata Pink Sheet
Cynata Therapeutics financial ratios help investors to determine whether Cynata Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cynata with respect to the benefits of owning Cynata Therapeutics security.